OND reorganization moves forward
The FDA said Thursday that the planned reorganization of its Office of New Drugs (OND) will move forward thanks to Congressional approval, including changes to its Office of Translational Sciences (OTS) and the Office of Pharmaceutical Quality (OPQ).
The changes will create offices for interrelated disease areas and divisions with clearer and more focused expertise, the FDA said, noting the number of OND offices that oversee its review divisions will increase from six to eight, and there will be increases in the number of OND clinical divisions from 19 divisions to 27, plus six non-clinical review divisions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.